← Leaderboards
Sunday O Akintoye
University Of Pennsylvania
$3,651,037
Attributed
$3,651,037
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $588.3K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,651,037 · 7
By mechanism
R01$1,460,856 · 1
K08$691,761 · 1
K22$589,032 · 1
R21$432,000 · 1
R56$400,000 · 2
R03$77,388 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPropertyCellsHealingSiteOperative Surgical ProceduresMandible/MaxillaTumorBoneMandibleNeural CrestIn VitroQuality Of LifeComplicationBone MarrowMesodermHealedIrradiationTissuesOsteoradionecrosisBone RegenerationOsteogenesisOsteogenicRadiation
Grant awards (17)
Biological Indicators of Racial Disparity in Ameloblastoma Recurrence$371,719
R01 · FY2025 · CA · contact PI
Biological Indicators of Racial Disparity in Ameloblastoma Recurrence$353,134
R01 · FY2024 · CA · contact PI
Biological Indicators of Racial Disparity in Ameloblastoma Recurrence$364,284
R01 · FY2023 · CA · contact PI
Novel therapeutic approaches to remediate radiotherapy-induced bone necrosis$200,000
R56 · FY2023 · CA · contact PI
Biological Indicators of Racial Disparity in Ameloblastoma Recurrence$371,719
R01 · FY2022 · CA · contact PI
Complications of Jaw Osteoradionecrosis in Cancer Management$196,344
K22 · FY2014 · CA · contact PI
Dental outcomes in Fibrous Dysplasia/McCune Albright Syndrome$200,000
R56 · FY2013 · DE · contact PI
Complications of Jaw Osteoradionecrosis in Cancer Management$196,344
K22 · FY2013 · CA · contact PI
Intracellular trafficking of Bisphosphonates in bone mesenchymal Stem Cells$192,000
R21 · FY2013 · DE · contact PI
Intracellular trafficking of Bisphosphonates in bone mesenchymal Stem Cells$240,000
R21 · FY2012 · DE · contact PI
Complications of Jaw Osteoradionecrosis in Cancer Management$196,344
K22 · FY2012 · CA · contact PI
Treatment of Osteoradionecrosis with Bone Marrow Stromal Cells$138,381
K08 · FY2010 · CA · contact PI
Treatment of Osteoradionecrosis with Bone Marrow Stromal Cells$138,333
K08 · FY2009 · CA · contact PI
Treatment of Osteoradionecrosis with Bone Marrow Stromal Cells$138,333
K08 · FY2008 · CA · contact PI
Treatment of Osteoradionecrosis with Bone Marrow Stromal Cells$138,381
K08 · FY2007 · CA · contact PI
Treatment of Osteoradionecrosis with Bone Marrow Stromal Cells$138,333
K08 · FY2006 · CA · contact PI
Regulatory Kinases in BMP-mediated hMSC Osteogenesis$77,388
R03 · FY2006 · AG · contact PI